CardioGenics (CGNH) Stock Price, News & Analysis

Company Overview

CardioGenics Holdings, Inc., traded under the symbol CGNH, is a life sciences firm focused on the research, development and commercialization of immunodiagnostic assays aimed at improving cardiovascular patient care. Leveraging proprietary monoclonal antibody technologies, the company designs and produces enzyme‐linked immunosorbent assays (ELISA), chemiluminescent immunoassays and point‐of‐care test kits that detect critical cardiac biomarkers such as B‐type natriuretic peptide (BNP) and cardiac troponin I. These assays provide clinicians with timely insights into heart failure and acute coronary syndromes, enabling more informed treatment decisions in emergency and hospital settings.

CardioGenics’ product portfolio includes high‐sensitivity and rapid‐turnaround immunoassays suitable for central laboratories as well as decentralized point‐of‐care platforms. The company’s flagship BNP assay has achieved regulatory approvals in key markets across North America, Europe and Latin America, with established distribution channels in multiple countries. By partnering with regional distributors and contract manufacturing organizations, CardioGenics ensures broad commercial access and tailored solutions for healthcare providers seeking to enhance diagnostic workflows.

Since its founding in 2000, CardioGenics has combined academic research collaborations with in‐house expertise in immunochemistry, assay development and quality management. Headquartered in Palm Beach Gardens, Florida, the company maintains research and manufacturing facilities stateside and abroad. Guided by a management team of veterans from the diagnostics and biotechnology sectors, CardioGenics continues to advance its pipeline of novel biomarker assays and expand its global footprint in cardiovascular diagnostics.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CGNH Stock Analysis - Frequently Asked Questions

How do I buy shares of CardioGenics?

Shares of CGNH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of CardioGenics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CardioGenics investors own include Trinity Biotech (TRIB), Samsung Electronics (SSNLF), Rock Creek Pharmaceuticals (RCPIQ), Merck & Co., Inc. (MRK), MediPharm Labs (MEDIF) and Labrador Iron Mines (LBRMF).

Company Calendar

• Today: 7/18/2025
• Fiscal Year End: 10/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Business Services
• Current Symbol: OTCMKTS:CGNH
• CIK: 1089029
• Web: www.cardiogenics.com
• Phone: (905) 673-8501
• Fax: 905-673-9865
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A